环孢素A治疗系统性红斑狼疮并血小板减少临床分析

The clinical analysis on the efficacy of CosA in treatment of SLE associated with thrombocytopenic

人住我院2006年8月至2009年1月确诊为系统性红斑狼疮（SLE）的10例患者，均伴有血小板（PLT）明显减少，维持在（20-50）×10^9／L至少3月以上。给予泼尼松0．5mg／（kg·d）及环孢素A150mg／d治疗，3个月后100ms／a疗程半年，观察患者临床表现，每个月检测SLE疾病活动指数（SLEDAI）、抗ds-DNA、尿蛋白、补体C3、红细胞沉降率（血沉）、C．反应蛋白（CRP）、肝功能、肾功能、血常规等，比较患者治疗前后各项指标的变化。结果显示治疗半年后患者血小板明显升高（P〈0．05），抗ds—DNA转阴、补体C3上升，红细胞沉降率（血沉）、C-反应蛋白较治疗前明显下降（P〈0．05）。提示泼尼松联合环孢素A治疗SLE合并顽固性血小板减少的疗效明显，副作用小。

Ten patients admitted in our hospital during Aug. 2036 to Jan. 2009 diagnosed with systemic lupus erythematosus associated with thrombocytopenic whose PLT had been at a level of （20-50） × 10^9/L over three months were given 0.5 mg/（kg · d） of prednisone and 150 mg/d of ciclosporin A for 3 months and then 100 mg/d of eielosporin A for half a year. The clinical manifestations of patients were observed and their SLEDAI, anti-ds DNA, urine protein, C3, ESR, CRP, hepatic function, renal function and complete blood cell count were detected every month. A comparison be- tween the clinical parameters before and after treatment revealed that the： number of platelet increased largely （ P 〈 0.05）, anti-ds DNA became negative, C3 was higher, ESR and CRP were decreased obviously （P 〈0.05） after treatment. The result suggests that predmsone combined ciclosporin A is effective in the treatment of SLE associated with thrombocytopehie, with little side effects.